CSF1R and benign prostatic hyperplasia: Inhibition of this pathway with sunitinib, CSF1R silencing, or ligand neutralization was associated with reduced fibroblast-induced proliferation in vitro and attenuated prostate enlargement in an androgen-induced BPH mouse model (Fig. 6l).